Abstract:Abstract. This study aimed to assess the impact of recombinant human brain natriuretic peptide (rh-BNP) on ventricular function and hemodynamics in post-ST-segment elevation myocardial infarction (STEMI). We compared the outcomes of 65 STEMI patients treated with rh-BNP to an equal cohort given tirofiban following percutaneous coronary intervention (PCI). Data collected pre- and post-intervention included biochemical markers, TIMI (Thrombolysis In Myocardial Infarction) grade, hemodynamics, thrombotic score (TS), left ven-tricular ejection fraction (LVEF), high-sensitivity C-reactive protein (CRP) levels, liver and kidney function, and ECG. The TIMI level (p=0.03), the ratio of TIMI myocardial perfusion grade III (p=0.04), and the thrombus score (p<0.001) in the rh-BNP group after the intervention markedly exceeded those in the tirofiban group. After correction, the TIMI frame count (CTFC) (p=0.02), the incidence of slow flow (p=0.02), thrombus score (p<0.001), stent length (p=0.02) as well as times of administration of sodium nitroprusside medication in the rh-BNP group were markedly below those in the tirofiban group (p=0.01). Creatine ki-nase (CK) (p<0.001), CK-MB (p=0.01), and N-terminal pro-b-type natriuretic peptide (NT-proBNP) (p<0.02) in the rh-BNP group were markedly below those the in tirofiban group 24 hours after intervention; and the sum-STR (p<0.03) immediately after intervention markedly exceeded that in the tirofiban group. No significant differences were found in major cardiac adverse events (MACE) between the treatments. At the 30-day follow-up, rh-BNP showed a more effective enhancement of blood flow status, with the safety profiles of both treatments be-ing comparable. The findings suggest that the rh-BNP has significant potential for treating PPCI-related slow flow.
What problem does this paper attempt to address?
The problem that this paper attempts to solve is, in patients with ST - segment elevation myocardial infarction (STEMI), the effects of recombinant human brain natriuretic peptide (rh - BNP) and tirofiban on improving ventricular function and hemodynamics after percutaneous coronary intervention (PCI). Specifically, the study aims to evaluate whether rh - BNP can more effectively reduce PCI - related slow - flow or no - reflow phenomena, and improve patients' left ventricular ejection fraction (LVEF), hemodynamic parameters, and biochemical indicators such as creatine kinase (CK), creatine kinase - MB (CK - MB), and N - terminal pro - B - type natriuretic peptide (NT - proBNP) levels.
### Research Background
- **ST - segment elevation myocardial infarction (STEMI)**: This is a serious heart disease, usually caused by plaque rupture in the coronary artery leading to thrombosis, completely blocking the blood vessel, thereby interrupting the blood supply to the myocardium.
- **Treatment strategies**: Currently, the main treatment for STEMI is to restore coronary blood flow through PCI or thrombolytic therapy. Adjuvant treatments include anti - platelet drugs, anticoagulants, β - blockers, and angiotensin - converting enzyme inhibitors, etc.
- **Recombinant human brain natriuretic peptide (rh - BNP)**: This is a synthetic form of the natural brain natriuretic peptide, which has the functions of vasodilation, diuresis, and inhibition of the renin - angiotensin - aldosterone system, helping to reduce cardiac load and improve myocardial recovery.
### Research Objectives
- **Compare the effects of rh - BNP and tirofiban**: The study aims to evaluate the advantages of rh - BNP in improving ventricular function and hemodynamics by comparing the efficacy of rh - BNP and tirofiban after PCI.
- **Evaluate safety**: The study also focuses on the safety of the two drugs, especially the incidence of major adverse cardiovascular events (MACE).
### Methods
- **Study design**: This is a retrospective study. A total of 142 STEMI patients treated in the hospital from June 2021 to June 2023 were included, and finally 130 patients participated in the experiment.
- **Grouping**: 65 patients received rh - BNP treatment, and 65 patients received tirofiban treatment.
- **Treatment regimens**: All patients took 300 mg of aspirin, 300 mg of clopidogrel or 180 mg of ticagrelor orally upon admission, and were given 5000 IU of heparin by intravenous injection. In the rh - BNP group, 5 mg of rh - BNP was given during PCI and after stent implantation respectively; in the tirofiban group, 5 mg/kg of tirofiban was given during PCI and after stent implantation respectively.
- **Data collection**: The study collected multiple preoperative and postoperative indicators of patients, including TIMI grading, hemodynamic parameters, thrombus score (TS), LVEF, CRP levels, liver and kidney functions, and electrocardiograms, etc.
### Results
- **Main findings**:
- The rh - BNP group was significantly superior to the tirofiban group in TIMI grading, the proportion of TIMI myocardial perfusion grade III, and thrombus score.
- At 24 hours after surgery, the levels of CK, CK - MB, and NT - proBNP in the rh - BNP group were significantly lower than those in the tirofiban group.
- The change in LVEF in the rh - BNP group was significantly greater than that in the tirofiban group.
- Immediately after surgery, the total ST - segment resolution (sum - STR) in the rh - BNP group was significantly higher than that in the tirofiban group.
- There was no significant difference in the incidence of major adverse cardiovascular events (MACE) between the two groups during the 30 - day follow - up period.
### Discussion
- **Advantages of rh - BNP**: The research results show that rh - BNP has a significant advantage in improving PCI - related slow - flow or no - reflow phenomena in STEMI patients, and can also effectively improve ventricular function and hemodynamics.
- **Safety**: The safety of rh - BNP and tirofiban is comparable, with no obvious serious side effects.
- **Limitations**: The study is of retrospective design, which may be biased; the sample size is small; and there is a lack of long - term follow - up data.
### Conclusion
- **Clinical application potential**: The research results support the potential application value of rh - BNP in PCI treatment of STEMI patients, especially in improving slow - flow or no - reflow phenomena. However, larger - scale prospective studies are needed in the future to further verify these findings.